Views: 0 Author: Site Editor Publish Time: 2021-08-20 Origin: Site
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment for COVID-19 (TEMPOL: A Potential Home Treatment for COVID-19 | NIH COVID-19 Research). The NIH news stated that, “This treatment would likely prevent severe disease.” The article went on to describe how Tempol could reduce COVID-19 symptoms by calming inflammation, protecting organs from damage, and decreasing the clumping of platelets.
This is a great news to the global pandemic. Especially at this period when moreore treatments for COVID-19 are critically needed. And the U.S. Food & Drug Administration (FDA) has given the go-ahead to Adamis Pharmaceuticals to conduct a clinical study using Tempol as an at home treatment to prevent disease progression and thereby releasing the burden of COVID-19 on the healthcare system. Adamis plans to initiate the study shortly.
But how could TEMPOL relieve the symptoms of COVID-19? Researchers found that SARS-CoV-2 needs clusters of iron and sulfur minerals to replicate in cells. TEMPOL breaks up these clusters and stops the virus from multiplying. This action might prevent severe COVID-19. And there are basically three ways of TEMPOL to reduce the symptoms.
Calming inflammation. SARS-CoV-2 infection sometimes causes an out-of-control immune response called a cytokine storm, which can damage the lungs and other organs and may cause death. TEMPOL may help prevent cytokine storms.
Protecting organs from damage.TEMPOL’s antioxidant activity may protect cells by inactivating free radicals — unstable molecules made by out-of-control immune responses — that can damage organs.
Decreasing clumping of platelets. Platelets are blood cells that help stop bleeding. If they are too sticky and form clumps in blood vessels, as can happen in people with COVID-19, dangerous blood clots can result. TEMPOLmay reduce this risk.
For more information, turn to:
NIH's press release announces the findings of research on TEMPOL’s ability to limit SARS-CoV-2 infection.
A clinical trial will test the ability of TEMPOL to reduce hospitalizations for people with COVID-19.
NIH’s COVID-19 Treatment Guidelines provide clinicians with evidence-based recommendations on the management of COVID-19.
Nanjing Liskon Biological Technology Co.,Ltd. is a high-tech enterprise focusing on chemical development, production, sales, import and export trade.